{
    "nct_id": "NCT04601857",
    "official_title": "A Phase 2 Study Evaluating Futibatinib (TAS 120) Plus Pembrolizumab in the Treatment of Advanced or Metastatic Urothelial Carcinoma",
    "inclusion_criteria": "1. Willing and able to provide written informed consent for the trial.\n2. Age ≥ 18 years of age\n3. Histologically confirmed advanced or metastatic urothelial carcinoma who have not received systemic treatment for advanced metastatic disease.\n\n   1. Cohort A: must have an FGFR3 mutation or FGFR1-4 fusion/rearrangement.\n   2. Cohort B: all other patients with UC (including patients with other FGFR or non-FGFR genetic aberrations and patients with wild-type [non-mutated] tumors)\n4. Unfit for or intolerant to standard platinum-based chemotherapy.\n5. Have an Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 to 1.\n6. Adequate organ function.\n7. Have a measurable disease per RECIST 1.1\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "1. Have received prior therapy with anti-PD-1, anti-PD-L1/L2 agent or FGFR inhibitor.\n2. History and/or current evidence of any of the following disorders:\n\n   1. Non-tumor related alteration of the calcium-phosphorus homeostasis that is considered clinically significant in the opinion of the Investigator.\n   2. Ectopic mineralization/calcification considered clinically significant in the opinion of the Investigator.\n   3. Retinal or corneal disorder considered clinically significant in the opinion of the Investigator.\n3. Has received a live vaccine within 30 days prior to the first dose of study drug.\n4. Have an active autoimmune disease that has required systemic treatment in the past 2 years.\n5. Have a history of (noninfectious) pneumonitis that required steroids or has current pneumonitis.\n6. Have had an allogenic tissue/ organ transplant.\n7. Has known human immunodeficiency virus (HIV) and/or history of Hepatitis B or C infections, or known to be positive for Hepatitis B antigen (HBsAg)/ Hepatitis B virus (HBV) DNA or Hepatitis C Antibody or RNA.\n8. Have known active central nervous system metastases and/or carcinomatous meningitis.\n9. Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy.\n10. Has severe hypersensitivity (≥Grade 3) to pembrolizumab and/or any of its excipients.",
    "miscellaneous_criteria": ""
}